Browsing by Author "Sousa, L."
Now showing 1 - 6 of 6
Results Per Page
Sort Options
- Diagnóstico pela Imagem - Quiz RadiológicoPublication . Sousa, L.
- Pancreas Burkitt primary lymphoma in pediatric agePublication . Araújo, J.; Sampaio-Macedo, C.; Sousa, L.We present an the case of an eight-year-old Portuguese boy with no history of traveling, admitted with non-specific abdominal pain. An analytic study revealed high levels of lipase and amylase. Ultrasound, abdominal computerized tomography (CT), and an abdominal magnetic resonance imaging (MRI), were performed. The imaging findings are suggestive of a pancreatic tumor which is an extremely rare entity in children. A biopsy was performed by opened surgery and identified a Burkitt lymphoma.
- Puberdade precoce secundária a quisto ovárico - caso clínicoPublication . Guimarães, T.M.; Tavares, M.; Oliveira, M.J.; Sousa, L.; Borges, T.Introdução: Os quistos do ovário são raros na criança pré-púbere, representando os quistos funcionantes 5% dos casos. A manifestação clínica mais comum é o desenvolvimento de puberdade precoce isossexual. Caso clínico: Rapariga de cinco anos e cinco meses, observada por hemorragia vaginal. Sem antecedentes pessoais ou familiares relevantes. No exame físico objetivou-se perda hemática vaginal e botão mamário bilateral. A ecografia abdominopélvica revelou quisto ovárico direito com 30mm. A investigação hormonal, incluindo função tiroideia não demonstrou alterações, exceto estradiol 38pg/mL. Prova LHRH com resposta pré-púbere. Sem aceleração da idade óssea nem da velocidade de crescimento. Acompanhada em consulta de Endocrinologia Pediátrica, sem recorrência de metrorragia, verificou-se regressão da telarca, associada a involução da lesão quística anexial direita. Discussão/Conclusões: A maioria dos quistos ovários involuem espontaneamente com regressão dos sinais de puberdade precoce, tal como no caso descrito. A terapêutica médica, com agonista GnRH, poderá ser útil nos casos de transformação de puberdade precoce periférica em central por quistos ováricos recorrentes e em situações que cursem com compromisso significativo da estatura alvo.
- REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in PortugalPublication . Batista, S.; Nunes, C. C.; Cerqueira, J. J.; Martins da Silva, Ana; Correia de Sá, J.; Ferreira, J.; Mendonça, M. T.; Pinheiro, J.; Salgado, V.; Correia, A. S.; Sequeira, J.; Costa, A.; Sousa, L.ackground: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). Objectives: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. Methods: Retrospective, multicentre, non-interventional study, reporting 3 years follow-up of data collected from October 2015 to July 2016. Sociodemographic data and previous treatments at baseline and data regarding disease evolution, including number of relapses, annualised relapse rates (ARR) and Expanded Disability Status Scale (EDSS), were collected. Results: Two-hundred and seventy-five participants were enrolled in the REALMS study. Results showed that the main reason to switch to fingolimod was failure of previous treatment (56.7%) and only 3.6% were naïve patients. In the total population, there was a significant decrease in ARR of 64.6% in the first year of treatment, 79.7% in the second year and 82.3% in the third year, compared with baseline. More than 67.0% of patients had no relapses during the 3 years after switching to fingolimod. EDSS remained stable throughout the study. Conclusions: Therapy with fingolimod showed a sustained effectiveness and safety over the 3 years, particularly on patients switched from first-line drugs (BRACE). No new safety issues were reported.
- The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective studyPublication . Sousa, L.; de Sa, J.; Sa, M.; Cerqueira, J.; Martins-Silva, A.INTRODUCTION: Studies have shown that natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). To date, no data are available in Portuguese patients. AIM: To determine the efficacy and safety of natalizumab in patients with RRMS in routine clinical practice in Portugal. PATIENTS AND METHODS: Clinical data for adult patients with RRMS treated with natalizumab at specialist neurology centres in Portugal were entered retrospectively into a database for analysis between October 2010 and February 2012. Changes in annualized relapse rates (ARR), Expanded Disability Status Scale (EDSS) scores and disability status were analysed. RESULTS: A total of 383 patients from 20 centres were included. Prior to starting natalizumab, the baseline median EDSS score was 4 and the mean ARR was 1.64. Most patients had previously received multiple sclerosis treatment (93.0%). Median natalizumab treatment duration was 12 months. Natalizumab treatment was associated with significant (p < 0.001) reductions from baseline in the mean ARR and EDSS scores in patients treated with natalizumab for >= 12 months (n = 288) and for >= 24 months (n = 160). Natalizumab was more effective in patients with less disability (EDSS < 3) and in those who had not previously received disease-modifying treatments. Two cases of progressive multifocal leukoencephalopathy were reported. No new unexpected adverse events occurred. CONCLUSION: Natalizumab is well tolerated, and is effective in reducing relapse rate and stabilising disease in patients with RRMS in the clinical practice setting in Portugal. Its efficacy persists with continued treatment, and it may be particularly effective in patients with less disability and without prior disease modifying therapy.
- The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective studyPublication . Sousa, L.; Sá, J.; Sá, M.; Cerqueira, J.; Martins-Silva, A.INTRODUCTION. Studies have shown that natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS). To date, no data are available in Portuguese patients. AIM. To determine the efficacy and safety of natalizumab in patients with RRMS in routine clinical practice in Portugal. PATIENTS AND METHODS. Clinical data for adult patients with RRMS treated with natalizumab at specialist neurology centres in Portugal were entered retrospectively into a database for analysis between October 2010 and February 2012. Changes in annualized relapse rates (ARR), Expanded Disability Status Scale (EDSS) scores and disability status were analysed. RESULTS. A total of 383 patients from 20 centres were included. Prior to starting natalizumab, the baseline median EDSS score was 4 and the mean ARR was 1.64. Most patients had previously received multiple sclerosis treatment (93.0%). Median natalizumab treatment duration was 12 months. Natalizumab treatment was associated with significant (p < 0.001) reductions from baseline in the mean ARR and EDSS scores in patients treated with natalizumab for >= 12 months (n = 288) and for >= 24 months (n = 160). Natalizumab was more effective in patients with less disability (EDSS < 3) and in those who had not previously received disease-modifying treatments. Two cases of progressive multifocal leukoencephalopathy were reported. No new unexpected adverse events occurred. CONCLUSION. Natalizumab is well tolerated, and is effective in reducing relapse rate and stabilising disease in patients with RRMS in the clinical practice setting in Portugal. Its efficacy persists with continued treatment, and it may be particularly effective in patients with less disability and without prior disease modifying therapy.